On October 2, 2020 Medscape reported that The International Association for the Study of Lung Cancer (IASLC) has selected Medscape Oncology as its partner to host and manage these IASLC virtual conferences in 2020 (Press release, Medscape, OCT 2, 2020, View Source [SID1234567992]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

– IASLC 2020 Hot Topic Meeting: Liquid Biopsy: A worldwide virtual event scheduled for
October 2-3, 2020
– IASLC 2020 North America Conference on Lung Cancer (NACLC): A worldwide virtual event scheduled for October 16-17, 2020

In collaboration with the IASLC, Medscape Oncology and MedscapeLIVE! will offer an immersive and engaging conference learning environment reaching the members of the thoracic oncology community including physicians, nurses, other clinicians, researchers and scientists as well as patients, survivors and advocates in the field of lung cancer.

The two conferences will include interactive educational sessions, late-breaking research, live chats with industry and e-poster presenters, interactive breakout sessions, networking opportunities and Virtual Exhibit Halls with product theaters.

"We are pleased to partner with Medscape in the delivery of the IASLC’s remaining 2020 meetings. The MedscapeLIVE! virtual conference platform and production services allow us to accomplish our mission of using all available means to deliver quality education to eliminate lung cancer and other thoracic malignancies. This partnership allows us to share important information with a global audience through live stream and on-demand content—while allowing us to protect the health of our members and their respective communities," said Dave Mesko, IASLC Chief Executive Officer.

The IASLC’s Mission

To embrace the study of the etiology, epidemiology, prevention, diagnosis, treatment and all other aspects of lung cancer and other thoracic malignancies.
To provide education and information about lung cancer and other thoracic malignancies to IASLC members, to the medical community at large, and to the public.
To use all available means to eliminate lung cancer and other thoracic malignancies as a health threat for the individual patient and throughout the world.
"We are honored to partner with the IASLC to offer comprehensive and immersive virtual meetings. As we are during a time of great change, it is more important than ever that healthcare providers across the world have access to digital education that aids in their ability to stay current with the latest changes in their field. We are excited to be working with the IASLC to deliver this critical information and impact provider practices and patient care," said Rejéan Rochette, Group General Manager, Medscape Education.

To learn more about the IASLC’s upcoming meetings, visit View Source

About the International Association for the Study of Lung Cancer

The International Association for the Study of Lung Cancer (IASLC) is the only global network dedicated to the study and eradication of lung cancer and other thoracic malignancies. Since its founding in 1974, the association’s membership has grown to more than 8,000 lung and thoracic cancer specialists from all disciplines in more than 100 countries.

By hosting global conferences, funding cutting-edge research and educating the health care community and the public about thoracic cancers, the IASLC works to alleviate the burden lung cancer places on patients, families and communities.

Each year, the IASLC hosts the World Conference on Lung Cancer (WCLC), the world’s largest meeting dedicated solely to thoracic cancers. The WCLC attracts more than 7,500 lung cancer specialists from across the world and offers attendees networking opportunities while providing a podium for practice-changing research.

In keeping with their commitment to education, the IASLC publishes the Journal of Thoracic Oncology (JTO), a primary source for thoracic malignancy prevention, detection, diagnosis and treatment information. The JTO serves as an authoritative resource in the field, with its impact factor increased from 12.460 in 2018 to 13.357 in 2019. Additionally, at the beginning of 2020, the IASLC launched a gold open-access publication to accompany the JTO entitled JTO Clinical and Research Reports.

On October 2, 2020 BD (Becton, Dickinson and Company) (NYSE:BDX) reported that it will conduct a live webcast of its fourth fiscal quarter and full fiscal year 2020 earnings conference call on Thursday, November 5, 2020, at 8:00 a.m. (ET) (Press release, BD Pharmaceutical Systems, OCT 2, 2020, View Source [SID1234567991]). BD will issue a press release detailing the quarter’s earnings earlier that morning.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The webcast of the conference call, along with related slides, will be accessible through BD’s website at www.bd.com/investors and will be available for replay through Thursday, November 12, 2020.

On October 2, 2020 Unum Group (NYSE: UNM) reported that it will release its third quarter 2020 results October 27, at approximately 4:15 p.m. Eastern time (Press release, Unum Therapeutics, OCT 2, 2020, https://www.prnewswire.com/news-releases/unum-group-to-release-third-quarter-2020-results-and-host-conference-call-301145053.html [SID1234567989]). The earnings release and financial supplement will be available in the Investors section of the company’s website, which can be directly accessed at www.investors.unum.com.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Members of Unum Group senior management will host a conference call Wednesday, October 28, at 8 a.m. Eastern time to discuss the results of operations for the third quarter. Topics may include forward-looking information, such as guidance on future results or trends in operations, as well as other material information. Interested parties are invited to listen and participate in the question-and-answer segment by dialing the appropriate number.

A live webcast of the call will be accessible from the Investors section of the company’s website in a listen-only mode. It is recommended that interested parties access the webcast approximately 5-10 minutes prior to the start of the call. The company will maintain a replay of the call on its website through Wednesday, November 4. Interested parties may access the replay by dialing the appropriate number.

On October 2, 2020 Select Medical Holdings Corporation ("Select Medical") (NYSE: SEM), reported that it will release the financial results for its third quarter ended September 30, 2020 on Thursday, October 29, 2020 after the market closes (Press release, Select Medical, OCT 2, 2020, View Source [SID1234567988]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Select Medical will host a conference call regarding its third quarter results, as well as the impact of the COVID-19 pandemic on each of its reporting segments, on Friday, October 30, 2020, at 9:00am ET. The domestic dial in number for the call is 1-866-440-2669. The international dial in number is 1-409-220-9844. The conference ID for the call is 6297066. The conference call will be webcast simultaneously and can be accessed at Select Medical Holdings Corporation’s website www.selectmedicalholdings.com.

For those unable to participate in the conference call, a replay will be available until 11:00am ET, November 6, 2020. The replay number is 1-855-859-2056 (domestic) or 1-404-537-3406 (international). The conference ID for the replay will be 6297066. The replay can also be accessed at Select Medical Holdings Corporation’s website, www.selectmedicalholdings.com.

On October 2, 2020 Agendia, Inc., a world leader in precision oncology for breast cancer, reported the presentation of four studies at the 12th European Breast Cancer Conference (EBCC-12) (Press release, Agendia, OCT 2, 2020, View Source [SID1234567987]). The data include a poster on further stratification of subtyping with BluePrint in breast cancer, as well as oral presentations that focus on the MINDACT trial, with a general trial update and in-depth analyses on screen- versus interval-detected breast cancers and the use of MammaPrint to evaluate lobular cancers.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Following are the four data sets accepted to the EBCC-12, which can be found at www.conferences.eortc.org/ebcc12:

Screen-detected breast cancers have different tumor biology and better prognosis compared to interval breast cancers (Presentation #ORAL-011, 12:50-1:00PM CEST, 3 October)
Clinical Utility of MammaPrint testing in Invasive Lobular Carcinoma: Results from the MINDACT phase III trial (Presentation #ORAL-007, 1:50-2:00PM CEST, 2 October)
Updated results of the MINDACT trial: 70-gene signature to guide de-escalation of chemotherapy in early breast cancer (Presentation #ORAL-021, 1:00-1:10PM CEST, 3 October)
BluePrint Molecular Subtyping Recognizes Single and Dual Subtype Tumors with Implications for Therapeutic Guidance (Abstract #518, Poster Session B, 2 October)
Oral presentations for MammaPrint focused on sub-studies within the 9-year follow-up data for the ground-breaking MINDACT study. These data included:

An evaluation of the association between tumor biology and survival by mode of detection, which found that while both screen-detected and interval breast cancers showed very good 8-year DMFI rates, in patients with MammaPrint High Risk tumors, there was a significant difference in DMFI between screen- and interval-detected cancers. The results suggest that combining MammaPrint and the cancer detection method may improve risk stratification of patients with early stage breast cancer.
An analysis that showed that MammaPrint is a clinically useful test for patients diagnosed with invasive lobular carcinoma, the second most common histological subtype of breast cancer. In this evaluation, MammaPrint classified 16% of lobular tumors as genomically High Risk, for which more aggressive treatment would be recommended. In contrast, the assay classified 38% of this type of cancer as genomically Low Risk, for which the standard should be omission of chemotherapy even if the patient is clinically high risk. These data reinforce MammaPrint’s ability to help facilitate treatment decisions based on the biology of a tumor.
In addition, new data in a general MINDACT follow up was presented by Emiel Rutgers, M.D., Ph.D., FRCS, Chair and Professor in Surgical Oncology at the Netherlands Cancer Institute. The analysis confirmed the clinical utility of MammaPrint, with the data shown at EBCC-12 confirming that a MammaPrint Low Risk score can guide de-escalation of adjuvant chemotherapy in patients with clinically high risk breast cancer.

Finally, an Agendia-led study found that a small proportion of tissue samples (about 2%), when evaluated by the molecular subtyping test BluePrint, will display a dual genomic subtype instead of the typical single subtype. This secondary or even tertiary subtype, in some cases, has specific genomic characteristics that may help physicians understand the deeper biology of these tumors and the possible implications for treatment.

"These data are evidence of Agendia’s continuing commitment to support research to further our knowledge of breast cancer, for optimal patient care," said William Audeh, M.D., M.S., Chief Medical Officer at Agendia. "We are proud to share these multi-faceted data with the researchers, physicians, and advocates who will attend EBCC-12 and apply this information to improve treatment outcomes for their patients."

The variety of data accepted for inclusion at EBCC-12 underscore Agendia’s commitment to the pursuit of research that will allow for breast cancer patients and their care teams to confidently make the most personalized treatment decisions.

About MINDACT

MammaPrint, the 70-gene risk of recurrence assay for patients with early-stage breast cancer, is supported by level 1A clinical evidence from MINDACT, a landmark trial sponsored by the EORTC (EORTC-10041/BIG3-04). The study found that clinically high-risk patients with a MammaPrint Low Risk result could safely de-escalate treatment and forgo chemotherapy. Long-term follow-up data from MINDACT, presented at the 2020 Annual Meeting of the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper), confirmed and built upon the findings published in the New England Journal of Medicine in 2016.

The MINDACT trial enrolled 6,693 breast cancer patients. At the five-year follow-up mark, the trial showed that tumor analysis and reclassification by the MammaPrint 70-gene expression signature enabled a 46 percent reduction in the use of chemotherapy for clinically high-risk patients that were reclassified by the genetic assay to be genomically Low Risk. Nine-year follow-up data will be published in depth later this year, and further validate MINDACT as a positive de-escalation study for chemotherapy and continues to demonstrate MammaPrint’s clinical utility when determining a breast cancer patient’s need for chemotherapy.